CA2440753A1 - Cell-based detection and differentiation of disease states - Google Patents

Cell-based detection and differentiation of disease states Download PDF

Info

Publication number
CA2440753A1
CA2440753A1 CA002440753A CA2440753A CA2440753A1 CA 2440753 A1 CA2440753 A1 CA 2440753A1 CA 002440753 A CA002440753 A CA 002440753A CA 2440753 A CA2440753 A CA 2440753A CA 2440753 A1 CA2440753 A1 CA 2440753A1
Authority
CA
Canada
Prior art keywords
panel
probes
cancer
disease
markers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002440753A
Other languages
English (en)
French (fr)
Inventor
Norman J. Pressman
Kenneth S. Hirsch (Deceased)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MonoGen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2440753A1 publication Critical patent/CA2440753A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002440753A 2001-03-12 2002-03-12 Cell-based detection and differentiation of disease states Abandoned CA2440753A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27463801P 2001-03-12 2001-03-12
US60/274,638 2001-03-12
PCT/GB2002/001125 WO2002073204A2 (en) 2001-03-12 2002-03-12 Cell-based detection and differentiation of disease states

Publications (1)

Publication Number Publication Date
CA2440753A1 true CA2440753A1 (en) 2002-09-19

Family

ID=23049031

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002440753A Abandoned CA2440753A1 (en) 2001-03-12 2002-03-12 Cell-based detection and differentiation of disease states

Country Status (10)

Country Link
US (4) US20030199685A1 (enExample)
EP (1) EP1373896A2 (enExample)
JP (1) JP2004526154A (enExample)
KR (1) KR20030094281A (enExample)
CN (1) CN1554025A (enExample)
CA (1) CA2440753A1 (enExample)
IL (1) IL157872A0 (enExample)
NZ (1) NZ528205A (enExample)
WO (1) WO2002073204A2 (enExample)
ZA (1) ZA200307121B (enExample)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2350692A1 (en) * 1998-10-29 2000-05-11 Cell Works Inc. Multiple marker characterization of single cells
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
US7043500B2 (en) * 2001-04-25 2006-05-09 Board Of Regents, The University Of Texas Syxtem Subtractive clustering for use in analysis of data
US7298877B1 (en) * 2001-11-20 2007-11-20 Icad, Inc. Information fusion with Bayes networks in computer-aided detection systems
EP2261368A1 (en) * 2002-03-13 2010-12-15 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US7274809B2 (en) * 2002-08-29 2007-09-25 Perceptronix Medical, Inc. And British Columbia Cancer Agency Computerized methods and systems related to the detection of malignancy-associated changes (MAC) to detect cancer
EP2359689B1 (en) 2002-09-27 2015-08-26 The General Hospital Corporation Microfluidic device for cell separation and use thereof
EP1422526A1 (en) * 2002-10-28 2004-05-26 MTM Laboratories AG Method for improved diagnosis of dysplasias
CA2506066A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
US20040122705A1 (en) * 2002-12-18 2004-06-24 Sabol John M. Multilevel integrated medical knowledge base system and method
US20040122704A1 (en) * 2002-12-18 2004-06-24 Sabol John M. Integrated medical knowledge base interface system and method
US20040122707A1 (en) * 2002-12-18 2004-06-24 Sabol John M. Patient-driven medical data processing system and method
US20040122708A1 (en) * 2002-12-18 2004-06-24 Avinash Gopal B. Medical data analysis method and apparatus incorporating in vitro test data
US20040122706A1 (en) * 2002-12-18 2004-06-24 Walker Matthew J. Patient data acquisition system and method
US20040122709A1 (en) * 2002-12-18 2004-06-24 Avinash Gopal B. Medical procedure prioritization system and method utilizing integrated knowledge base
US20040122702A1 (en) * 2002-12-18 2004-06-24 Sabol John M. Medical data processing system and method
US20040122787A1 (en) * 2002-12-18 2004-06-24 Avinash Gopal B. Enhanced computer-assisted medical data processing system and method
US7490085B2 (en) * 2002-12-18 2009-02-10 Ge Medical Systems Global Technology Company, Llc Computer-assisted data processing system and method incorporating automated learning
US20040122703A1 (en) * 2002-12-19 2004-06-24 Walker Matthew J. Medical data operating model development system and method
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004071572A2 (en) * 2003-02-06 2004-08-26 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
CA2516553C (en) * 2003-02-20 2013-04-16 Genomic Health, Inc. Use of intronic rna to measure gene expression
US7668801B1 (en) * 2003-04-21 2010-02-23 At&T Corp. Method and apparatus for optimizing queries under parametric aggregation constraints
EP1631689A2 (en) * 2003-05-28 2006-03-08 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CA2527321A1 (en) * 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
WO2005039382A2 (en) * 2003-06-24 2005-05-06 Genomic Health Prediction of likelihood of cancer recurrence
EP1644858B1 (en) * 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US20100246837A1 (en) * 2009-03-29 2010-09-30 Krause Lee S Systems and Methods for Tuning Automatic Speech Recognition Systems
AU2004284434A1 (en) * 2003-10-16 2005-05-06 Genomic Health, Inc. qRT-PCR assay system for gene expression profiling
US7552035B2 (en) * 2003-11-12 2009-06-23 Siemens Corporate Research, Inc. Method to use a receiver operator characteristics curve for model comparison in machine condition monitoring
WO2005047451A2 (en) * 2003-11-12 2005-05-26 Trustees Of Boston University Isolation of nucleic acid from mouth epithelial cells
EP1681988B1 (en) 2003-11-12 2015-04-08 The Children's Hospital Medical Center Method for diagnosis and treatment of pulmonary disorders
JP5192632B2 (ja) * 2003-12-12 2013-05-08 愛知県 肺癌組織中の遺伝子発現強度を識別する方法
JP4718490B2 (ja) 2003-12-23 2011-07-06 ジェノミック ヘルス， インコーポレイテッド フラグメント化ｒｎａの全般的増幅
DE102004009934A1 (de) * 2004-02-26 2005-09-22 Niendorf, Axel, Prof.Dr.med. Verfahren zur Untersuchung einer Gewebeprobe
CA2848463A1 (en) 2004-04-09 2005-10-27 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US7991557B2 (en) * 2004-06-19 2011-08-02 Genenews Corporation Computer system and methods for constructing biological classifiers and uses thereof
CA2571180A1 (en) * 2004-06-19 2006-01-05 Chondrogene, Inc. Computer systems and methods for constructing biological classifiers and uses thereof
CN101115848A (zh) * 2004-11-03 2008-01-30 阿尔马科诊断有限公司 转录组微阵列技术及应用该技术的方法
JP4939425B2 (ja) 2004-11-05 2012-05-23 ジェノミック ヘルス， インコーポレイテッド 乳癌の治療反応の予後および予測の分子指標
CA3061785A1 (en) * 2004-11-05 2006-05-18 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
US20060136259A1 (en) * 2004-12-17 2006-06-22 General Electric Company Multi-dimensional analysis of medical data
US20060136417A1 (en) * 2004-12-17 2006-06-22 General Electric Company Method and system for search, analysis and display of structured data
AU2006228990B8 (en) * 2005-04-01 2013-02-07 Medvet Science Pty. Ltd. A method of diagnosis and treatment and agents useful for same
EP1874920A4 (en) * 2005-04-05 2009-11-04 Cellpoint Diagnostics DEVICES AND METHOD FOR ENRICHING AND CHANGING CIRCULATING TUMOR CELLS AND OTHER PARTICLES
US20070196820A1 (en) 2005-04-05 2007-08-23 Ravi Kapur Devices and methods for enrichment and alteration of cells and other particles
EP1874962A2 (en) 2005-04-14 2008-01-09 The Trustees Of Boston University Diagnostic for lung disorders using class prediction
US8351665B2 (en) * 2005-04-28 2013-01-08 The General Hospital Corporation Systems, processes and software arrangements for evaluating information associated with an anatomical structure by an optical coherence ranging technique
US7766231B2 (en) * 2005-06-24 2010-08-03 Schneider Electric USA, Inc. Devices and methods for determining the amount of individual usage of a shared commodity
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
JP2009508493A (ja) 2005-09-19 2009-03-05 ベリデックス・エルエルシー すい臓がんを診断するための方法
US20070078873A1 (en) * 2005-09-30 2007-04-05 Avinash Gopal B Computer assisted domain specific entity mapping method and system
US9347945B2 (en) 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
EP1806587A1 (en) * 2006-01-07 2007-07-11 Université de Liège An in-vitro method for screening accessible biological markers in pathologic tissues
EP2605018A1 (en) * 2006-03-09 2013-06-19 The Trustees of the Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
WO2007109580A1 (en) * 2006-03-17 2007-09-27 Mayo Foundation For Medical Education And Research Assessing lung nodules
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
EP2029779A4 (en) 2006-06-14 2010-01-20 Living Microsystems Inc HIGHLY PARALLEL SNP GENOTYPING UTILIZATION FOR FETAL DIAGNOSIS
US7502767B1 (en) * 2006-07-21 2009-03-10 Hewlett-Packard Development Company, L.P. Computing a count of cases in a class
EP2084535B9 (en) * 2006-09-08 2016-09-07 Richard Porwancher Bioinformatic approach to disease diagnosis
US7599898B2 (en) * 2006-10-17 2009-10-06 International Business Machines Corporation Method and apparatus for improved regression modeling
EP2104744B1 (en) * 2007-01-16 2012-05-16 MUSC Foundation For Research Development Compositions and methods for diagnosing, treating, and preventing prostate conditions
US7892770B2 (en) * 2007-08-24 2011-02-22 Van Andel Research Institute Monoclonal antibody which binds cMet (HGFR) in formalin-fixed and paraffin-embedded tissues and related methods
US8541183B2 (en) 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
CN101990577A (zh) 2007-09-19 2011-03-23 波士顿大学理事会 鉴定肺病药物开发的新途径
WO2009049228A2 (en) * 2007-10-10 2009-04-16 The Regents Of The University Of Michigan Compositions and methods for assessing disorders
WO2009121070A1 (en) * 2008-03-28 2009-10-01 The Trustees Of Boston University Multifactorial methods for detecting lung disorders
WO2010021843A1 (en) * 2008-08-20 2010-02-25 Eli Lilly And Company Use of antifolates in patients with detectable levels of tff-1 for the cancer treatment
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
CA3011730C (en) * 2008-09-09 2022-05-17 Somalogic, Inc. Lung cancer biomarkers and uses thereof
HUE031848T2 (en) 2008-09-20 2017-08-28 Univ Leland Stanford Junior Non-invasive diagnosis of fetal aneuploidy by sequencing
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
GB2512153B (en) * 2008-11-17 2014-11-12 Veracyte Inc Methods and compositions of molecular profiling for disease diagnostics
US20100185568A1 (en) * 2009-01-19 2010-07-22 Kibboko, Inc. Method and System for Document Classification
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
EP3444359A1 (en) * 2009-03-12 2019-02-20 Cancer Prevention And Cure, Ltd. Methods of identification of non-small cell lung cancer
WO2010111656A2 (en) * 2009-03-27 2010-09-30 Life Technologies Corporation Systems and methods for assessing images
JP6078339B2 (ja) 2009-05-07 2017-02-08 ベラサイト インコーポレイテッド 甲状腺状態の診断のための方法および組成物
US20130143747A1 (en) * 2011-12-05 2013-06-06 Myriad Genetics, Incorporated Methods of detecting cancer
US8811535B2 (en) * 2009-07-17 2014-08-19 Mitre Corporation Time-frequency space constructions of families of signals
CA2717477A1 (en) * 2009-09-24 2011-03-24 Heidi E. Wagner Computer based standardized method and apparatus for guiding decision support for surgical anatomic pathology operations
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
JP6114035B2 (ja) * 2010-02-10 2017-04-12 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 肺癌検出用唾液バイオマーカー
JP5931874B2 (ja) 2010-08-13 2016-06-08 ソマロジック・インコーポレーテッド 膵癌バイオマーカーおよびその使用
GB2498283A (en) * 2010-09-08 2013-07-10 Nodality Inc Benchmarks for normal cell identification
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
WO2012070970A1 (ru) * 2010-11-22 2012-05-31 Farber Boris Slavinovich Диагностический способ для прогноза развития и контроля эффективности лечения онкологических заболеваний
WO2012070969A1 (ru) * 2010-11-22 2012-05-31 Farber Boris Slavinovich Диагностический способ для прогноза развития и контроля эффективности лечения сердечно-сосудистых заболеваний
WO2012129325A1 (en) * 2011-03-22 2012-09-27 The General Hospital Corporation Molecular analysis of tumor samples
WO2013045500A1 (en) * 2011-09-26 2013-04-04 Universite Pierre Et Marie Curie (Paris 6) Method for determining a predictive function for discriminating patients according to their disease activity status
CA2876405C (en) * 2012-06-14 2020-01-07 Erasmus University Medical Center Rotterdam Methods, reagents and kits for detecting minimal residual disease
US10158898B2 (en) 2012-07-26 2018-12-18 Comcast Cable Communications, Llc Customized options for consumption of content
US10526655B2 (en) 2013-03-14 2020-01-07 Veracyte, Inc. Methods for evaluating COPD status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
GB201316524D0 (en) * 2013-09-17 2013-10-30 Medical Res Council Biomarkers
DK3108256T3 (da) 2014-02-17 2020-09-21 Sienna Cancer Diagnostics Ltd Fremgangsmåde til detektering af cancer
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
EP3770274A1 (en) 2014-11-05 2021-01-27 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
JP6903672B2 (ja) * 2016-03-08 2021-07-14 マグアレイ，インコーポレイテッド 肺癌の診断および治療のための蛋白質と自己抗体バイオマーカー
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
EP4115891A1 (en) * 2016-08-05 2023-01-11 The Research Foundation for The State University of New York Keratin 17 as a biomarker for bladder cancer
WO2018187496A2 (en) 2017-04-04 2018-10-11 Lung Cancer Proteomics, Llc Plasma based protein profiling for early stage lung cancer prognosis
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
WO2019157214A2 (en) * 2018-02-07 2019-08-15 Ai Technologies Inc. Deep learning-based diagnosis and referral of diseases and disorders
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
CN110970131B (zh) * 2019-10-24 2024-01-26 中国医科大学附属盛京医院 一种基于免疫球蛋白定量检测的肾小球疾病分类分型模型及其应用
CN110807426B (zh) * 2019-11-05 2023-11-21 苏州华文海智能科技有限公司 一种基于深度学习的寄生虫检测系统及方法
CN113049344B (zh) * 2021-04-20 2022-02-01 深圳天烁生物科技有限公司 细胞染色的质控品制备方法
WO2023278468A1 (en) * 2021-06-29 2023-01-05 The Regents Of The University Of Michigan Methods of determining risk of and treating cancer recurrence
KR102830294B1 (ko) * 2021-07-30 2025-07-08 한국 한의학 연구원 유사 이미지 분류를 위한 딥 러닝 성능 향상 방법 및 장치
CN116178496A (zh) * 2022-12-08 2023-05-30 西安交通大学医学院第一附属医院 一种靶向识别神经内分泌肿瘤标志物insm1的短肽及其产品和应用
CN119199125A (zh) * 2024-10-31 2024-12-27 武汉大学 一种原位检测活循环恶性细胞中多重肺癌相关标志物及肿瘤异质化的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579827A (en) * 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
WO1987006620A1 (en) 1986-04-29 1987-11-05 Murex Corporation Diagnostic kit for sexually transmitted diseases
US4853770A (en) 1988-03-01 1989-08-01 Joe Schneller Video system for viewing microscopic specimens
US5784162A (en) * 1993-08-18 1998-07-21 Applied Spectral Imaging Ltd. Spectral bio-imaging methods for biological research, medical diagnostics and therapy
US5543291A (en) 1993-01-29 1996-08-06 Dana Farber Cancer Institute Method of detecting carcinoma
SK153594A3 (en) 1993-04-14 1995-07-11 Int Murex Tech Corp Determination method of antibodies to two or bigger number of different patogens in tested sample
EP0656070A4 (en) * 1993-05-24 1996-03-20 Amoco Corp NUCLEIC ACID SAMPLES FOR LEGIONELLA GENERATIONS.
IT1270951B (it) * 1993-06-07 1997-05-26 Boehringer Mannheim Italia Metodo e dispositivo per il rilevamento simultano di neisseria gonorrhoeae, chlamydia trachomatis e mycoplasma
EP0727664A3 (en) 1995-02-15 1996-11-20 Bayer Ag Tumor markers to detect the recurrence of breast cancer
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
US5895748A (en) 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
NO308755B1 (no) * 1996-12-20 2000-10-23 Iystein Fodstad FremgangsmÕte til karakterisering av unormale celler, anvendelse og sett for utførelse av fremgangsmÕten
DE69837529T2 (de) * 1997-02-12 2007-07-26 Electrophoretics Ltd., Cobham Proteinmarker für lungenkrebs und deren verwendung
CN1282422A (zh) 1997-10-21 2001-01-31 癌症研究行动技术有限公司 对细胞生长异常的测定
US6335170B1 (en) * 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
GB9926805D0 (en) 1999-11-13 2000-01-12 Zeneca Ltd Diagnostic methods
GB0018140D0 (en) * 2000-07-24 2000-09-13 Medical Res Council Screening for abnormalities
US7219016B2 (en) * 2001-04-20 2007-05-15 Yale University Systems and methods for automated analysis of cells and tissues

Also Published As

Publication number Publication date
ZA200307121B (en) 2004-12-13
NZ528205A (en) 2006-09-29
US6939670B2 (en) 2005-09-06
US20080139402A1 (en) 2008-06-12
US20030199685A1 (en) 2003-10-23
US20050282201A1 (en) 2005-12-22
JP2004526154A (ja) 2004-08-26
US20030104499A1 (en) 2003-06-05
EP1373896A2 (en) 2004-01-02
CN1554025A (zh) 2004-12-08
WO2002073204A3 (en) 2003-10-30
IL157872A0 (en) 2004-03-28
WO2002073204A2 (en) 2002-09-19
KR20030094281A (ko) 2003-12-11

Similar Documents

Publication Publication Date Title
US20030104499A1 (en) Cell-based detection and differentiation of lung cancer
Tanigawa et al. Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor
ZA200502575B (en) Cell-based detection and differentiation of disease states
Bravaccini et al. PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis
Sari et al. Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer
Ciancio et al. Prognostic value of p53 and Ki67 expression in fiberoptic bronchial biopsies of patients with non small cell lung cancer
Nishimura et al. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis
Rohan et al. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk
Burford et al. Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer
Van der Bij et al. Markers for the non-invasive diagnosis of mesothelioma: a systematic review
Mawas et al. MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung
Johnston et al. Use of a monoclonal antibody (B72. 3) as a novel immunohistochemical adjunct for the diagnosis of carcinomas in fine needle aspiration biopsy specimens
Soh et al. Immunoprofiling of colitis-associated and sporadic colorectal cancer and its clinical significance
Adkins et al. SOX10 and GATA3 in adenoid cystic carcinoma and polymorphous adenocarcinoma
Xi et al. Clinical significance of the histological and molecular characteristics of ependymal tumors: a single institution case series from China
Choi Pericardial malignant mesothelioma diagnosed in a dog by immunocytochemistry of the pericardial fluid: a case report
Kentrou et al. An improved flow cytometric assay for detection and discrimination between malignant cells and atypical mesothelial cells, in serous cavity effusions
Calo et al. Metastases to the parotid glands: An institutional experience
Schittenhelm et al. Diagnostic value of EAAT-1 and Kir7. 1 for distinguishing endolymphatic sac tumors from choroid plexus tumors
Shibahara et al. Primary MALT lymphoma of the breast: pathological and radiological characteristics
Brock et al. A comparison of estrogen receptor SP1 and 1D5 monoclonal antibodies in routine clinical use reveals similar staining results
Mazzucchelli et al. Immunohistochemical expression of prostate tumour overexpressed 1 (PTOV1) in atypical adenomatous hyperplasia (AAH) of the prostate: additional evidence linking AAH to adenocarcinoma
AU2002242823A1 (en) Cell-based detection and differentiation of disease states
Biancosino et al. Cytological diagnostic procedures in malignant mesothelioma
Noguchi et al. High programmed death ligand 1 expression in carcinomatous components predicts a poor prognosis in pulmonary pleomorphic carcinoma

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued